Cargando…
Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study
INTRODUCTION: Because of the cost, in the hemodialysis centers of Kinshasa, the double dose of hepatitis B (HBV) vaccine is administered only to HIV infected patients while other patients receive a single dose. This study aimed to evaluate the single-dose vaccination Protocol and identify determinan...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906547/ https://www.ncbi.nlm.nih.gov/pubmed/33708291 http://dx.doi.org/10.11604/pamj.2019.34.122.19603 |
_version_ | 1783655311903555584 |
---|---|
author | Kengibe, Pitchou Yemasai Makulo, Jean-Robert Risassy Nlandu, Yannick Mayamba Lepira, François Bompeka Sumaili, Ernest Kiswaya Bukabau, Justine Busanga Mbendi, Charles Nlombi Ahuka, Steve Mundeke Tshimpi, Antoine Wola Ngoma, Patrick Kisoko Mangani, Nseka Nazaire Mbendi, Sebastien Nsukini |
author_facet | Kengibe, Pitchou Yemasai Makulo, Jean-Robert Risassy Nlandu, Yannick Mayamba Lepira, François Bompeka Sumaili, Ernest Kiswaya Bukabau, Justine Busanga Mbendi, Charles Nlombi Ahuka, Steve Mundeke Tshimpi, Antoine Wola Ngoma, Patrick Kisoko Mangani, Nseka Nazaire Mbendi, Sebastien Nsukini |
author_sort | Kengibe, Pitchou Yemasai |
collection | PubMed |
description | INTRODUCTION: Because of the cost, in the hemodialysis centers of Kinshasa, the double dose of hepatitis B (HBV) vaccine is administered only to HIV infected patients while other patients receive a single dose. This study aimed to evaluate the single-dose vaccination Protocol and identify determinants of seroconversion's lack of anti-HBs after vaccination schedule. METHODS: 56 non-HIV chronic hemodialysis patients serologically negative for HBs Ag, anti-HBs and anti-HBc were selected between January 2014 and December 2016. The recombinant DNA vaccine (Euvax B(®)20 μg) was administered intramuscularly in the deltoid muscle at days 0, 30, 60 and 180. Serum anti-HBs titer was assayed at day 240. The endpoint was seroconversion, defined as anti-HBs titer ≥ 10 IU/l (10-99 IU/l = low protective vaccine response; ≥ 100 IU/l = highly protective vaccine response). Anti-HBs titer < 10 IU/l defined a lack of seroconversion. A Logistic regression model was used to identify factors associated with the lack of seroconversion. RESULTS: In the study group (mean age 55.6± 15.1 years; 73 % men, 36% diabetic and 86% hypertensive), low and highly protective vaccine responses were seen in 32% and 50% respectively versus 18% of patient had a lack of seroconversion. CRP > 6 mg/L (aOR: 8.96), hypoalbuminemia (aOR: 6.50) and KT/V < 1.2 (aOR: 3.70) were associated with the lack of seroconversion. CONCLUSION: Half of the patients in the study had either a lack or low protective vaccine response. Patient-related factors and hemodialysis parameters were the main factors associated with the lack of anti-HbS seroconversion. These results highlight the need to maximize doses of vaccine in all patients. |
format | Online Article Text |
id | pubmed-7906547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-79065472021-03-10 Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study Kengibe, Pitchou Yemasai Makulo, Jean-Robert Risassy Nlandu, Yannick Mayamba Lepira, François Bompeka Sumaili, Ernest Kiswaya Bukabau, Justine Busanga Mbendi, Charles Nlombi Ahuka, Steve Mundeke Tshimpi, Antoine Wola Ngoma, Patrick Kisoko Mangani, Nseka Nazaire Mbendi, Sebastien Nsukini Pan Afr Med J Research INTRODUCTION: Because of the cost, in the hemodialysis centers of Kinshasa, the double dose of hepatitis B (HBV) vaccine is administered only to HIV infected patients while other patients receive a single dose. This study aimed to evaluate the single-dose vaccination Protocol and identify determinants of seroconversion's lack of anti-HBs after vaccination schedule. METHODS: 56 non-HIV chronic hemodialysis patients serologically negative for HBs Ag, anti-HBs and anti-HBc were selected between January 2014 and December 2016. The recombinant DNA vaccine (Euvax B(®)20 μg) was administered intramuscularly in the deltoid muscle at days 0, 30, 60 and 180. Serum anti-HBs titer was assayed at day 240. The endpoint was seroconversion, defined as anti-HBs titer ≥ 10 IU/l (10-99 IU/l = low protective vaccine response; ≥ 100 IU/l = highly protective vaccine response). Anti-HBs titer < 10 IU/l defined a lack of seroconversion. A Logistic regression model was used to identify factors associated with the lack of seroconversion. RESULTS: In the study group (mean age 55.6± 15.1 years; 73 % men, 36% diabetic and 86% hypertensive), low and highly protective vaccine responses were seen in 32% and 50% respectively versus 18% of patient had a lack of seroconversion. CRP > 6 mg/L (aOR: 8.96), hypoalbuminemia (aOR: 6.50) and KT/V < 1.2 (aOR: 3.70) were associated with the lack of seroconversion. CONCLUSION: Half of the patients in the study had either a lack or low protective vaccine response. Patient-related factors and hemodialysis parameters were the main factors associated with the lack of anti-HbS seroconversion. These results highlight the need to maximize doses of vaccine in all patients. The African Field Epidemiology Network 2019-10-31 /pmc/articles/PMC7906547/ /pubmed/33708291 http://dx.doi.org/10.11604/pamj.2019.34.122.19603 Text en © Pitchou Yemasai Kengibe et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kengibe, Pitchou Yemasai Makulo, Jean-Robert Risassy Nlandu, Yannick Mayamba Lepira, François Bompeka Sumaili, Ernest Kiswaya Bukabau, Justine Busanga Mbendi, Charles Nlombi Ahuka, Steve Mundeke Tshimpi, Antoine Wola Ngoma, Patrick Kisoko Mangani, Nseka Nazaire Mbendi, Sebastien Nsukini Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study |
title | Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study |
title_full | Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study |
title_fullStr | Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study |
title_full_unstemmed | Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study |
title_short | Response to single dose hepatitis B vaccine in Congolese non-HIV hemodialysis patients: a prospective observational study |
title_sort | response to single dose hepatitis b vaccine in congolese non-hiv hemodialysis patients: a prospective observational study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906547/ https://www.ncbi.nlm.nih.gov/pubmed/33708291 http://dx.doi.org/10.11604/pamj.2019.34.122.19603 |
work_keys_str_mv | AT kengibepitchouyemasai responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT makulojeanrobertrisassy responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT nlanduyannickmayamba responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT lepirafrancoisbompeka responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT sumailiernestkiswaya responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT bukabaujustinebusanga responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT mbendicharlesnlombi responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT ahukastevemundeke responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT tshimpiantoinewola responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT ngomapatrickkisoko responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT manganinsekanazaire responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy AT mbendisebastiennsukini responsetosingledosehepatitisbvaccineincongolesenonhivhemodialysispatientsaprospectiveobservationalstudy |